
中文名称:P70S6K信号转导抑制剂(LY-2584702FREEBASE)
CAS号:1082949-67-4
分子式: C21H19F4N7 分子量: 445.42
产品形式: Free Base
研发状态: Completed
研发用途: Cancer
研究机构: Eli Lilly and Company
研发日期: Nov-10
研发阶段: Phase 1
LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM.
中文名称: 肌氨酸
CAS号:107-97-1
分子式: C3H7NO2 分子量: 89.09
产品形式: free base
研发状态: Completed
研发用途: Noise Exposure; Sleep Disturbance; Sleep Hygiene; Metabolic Disturbance; Cognitive Change
研究机构: Göteborg University; University of Pennsylvania; University of Manitoba
研发日期: April 24 2022
研发阶段: Not Applicable
Sarcosine (N-methylglycine, Sarcosinic acid, Methylaminoacetic acid, Methylglycine) is a competitive inhibitor of the type I glycine transporter (GlyT1) and an N-methyl-D-aspartate receptor (NMDAR) co-agonist.
中文名称:更昔洛韦钠
CAS号:107910-75-8
分子式: C9H12N5NaO4 分子量: 277.21
产品形式: Nucleoside
研发状态: Not yet recruiting
研发用途: Cytomegalovirus Infections; Kidney Transplant Infection; Pancreas Transplant
研究机构: University of Wisconsin Madison; Merck Sharp & Dohme LLC
研发日期: May-24
研发阶段: Phase 3
Ganciclovir Sodium (RS-21592, Cytovene IV, BW 759, 2'-Nor-2'-deoxyguanosine) is the sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV).
中文名称:氘右美沙芬
CAS号:1079043-55-2
分子式: C18H19D6NO 分子量: 277.43
产品形式: free base
研发状态: Recruiting
研发用途: Agitation in Patients With Dementia of the Alzheimer''s Type
研究机构: Otsuka Pharmaceutical Development & Commercialization Inc.
研发日期: Dec-15
研发阶段: Phase 3
Deudextromethorphan (AVP-786) is an active N-methyl-D-aspartate (NMDA) receptor antagonist.
中文名称:依西美坦
CAS号:107868-30-4
分子式: C20H24O2 分子量: 296.40
产品形式: free base
研发状态: Recruiting
研发用途: Diabetes Mellitus Type 2
研究机构: Novo Nordisk A/S
研发日期: February 26 2024
研发阶段: Phase 1
Exemestane (Aromasin,FCE24304, PNU155971,EXE) is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC50 of 30 nM and 40 nM, respectively.
中文名称:扎鲁司特
CAS号:107753-78-6
分子式: C31H33N3O6S 分子量: 575.68
产品形式: free base
研发状态: Terminated
研发用途: Breast Cancer
研究机构: University of California San Francisco
研发日期: March 13 2017
研发阶段: Phase 2
Zafirlukast (ICI-204219) is an oral leukotriene receptor antagonist (LTRA), used to prevent asthma symptoms.
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
